Therapeutics

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Omicron #Therapeutics

Breakthrough: New drug for Omicron and coronavirus strains 

Infex Therapeutics scientists have announced a breakthrough in laboratory trials of a new drug to treat Covid-19 and new variants of the disease, such as the Omicron variant.   Infex’s COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such,… Read More

#Covid-19 #News #Trending News

#Cancer research #Clinical trials #Drug therapy #Therapeutics

Phase I clinical study begins for patients with advanced liver cancer 

The National University Cancer Institute, Singapore (NCIS) and MiNA Therapeutics have dosed the first patients in an investigator-sponsored Phase I study of MiNA’s small activating RNA oligonucleotide, MTL-CEBPA, in combination with first-line standard of care, atezolizumab and bevacizumab, in patients with previously untreated, advanced hepatocellular carcinoma (HCC). Atezolizumab and bevacizumab are… Read More

#Cancer Research #News #Trending News

#Biology #Drug development #Therapeutics

Closing drug development gaps with new clinical prediction AI 

Quris, an artificial intelligence (AI) company in the pharmaceutical industry, has launched a clinical prediction AI platform to predict which drug candidates will safely work in humans. This will improve efficacy and cut drug development costs.   What do they do?  Quris uses AI-powered miniaturised “patients-on-a-chip” to avoid… Read More

#News #Videos

#Autoimmune disease #Biology #Drug development #Drug discovery #Research study #Therapeutics

Human-on-a-Chip approach validated to model rare autoimmune disease

A new peer-reviewed article demonstrated that Hesperos’ Human-on-a-Chip (HoaC) cell-based neuromuscular junction (NMJ) platform system can mimic the disease phenotypes of myasthenia gravis (MG). The manuscript, titled “A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics,” was published in Frontiers in Cell and Developmental Biology. Read More

#News

#Drug development #Drug discovery #GlobalData #siRNA #Therapeutics

Chinese pharma companies eye strategic alliances for therapeutics

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe, according to reporting by GlobalData. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances.  China pharma… Read More

#News #Trending News

#Brain disease #Cancer #Oncology #Small molecules #Therapeutics #Tumours

Hemispherian’s epigenetic therapeutics act on a new mechanism of action

Hemispherian is a Norwegian pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX) that target the TET2 enzyme. Lu Rahman spoke to Zeno Albisser, CEO, to find out more about the company’s expertise.  LR: What it does Hemispherian do?  ZA: We are focused on developing a novel class of small molecule drugs (GLIX)… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biologics #Drug development #Flow Cytometry #Immunogenicity #Therapeutics

Cellular assays to bridge the gap in immunogenicity prediction 

Listen to this article on the DDW Podcast: Dr. Urmi Roy, Global Product Manager for Flow Cytometry Reagents, Miltenyi Biotec, explains why immunogenicity prediction is a key consideration for therapeutic development.  Biologic drugs as therapy have improved the treatment of many diseases, but their success is often tempered by antidrug antibodies (ADAs),… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Biochemistry #Drug discovery #Drug targets #Mass spectrometry / NMR #Small molecules #Therapeutics

OMass unveils drug discovery pipeline for validated targets 

OMass Therapeutics has shared its pipeline of five novel, differentiated small molecule drug programmes, targeting intractable or inadequately drugged membrane and complex-bound protein targets such as GPCRs (G-protein-coupled receptors), solute carriers and intracellular protein complexes.  The company’s selected programmes focus on validated targets in immunology & rare disease indications with high unmet need. Read More

#News

#Drug development #Neuroscience #Therapeutics

Appointment seeks to boost brain disorder therapy development 

Inscopix, a brain mapping platform, appointed David Gray as Chief Scientific Officer (CSO) in a new position to discover and develop more effective therapies for brain disorders.  Inscopix provides brain research tools to basic and translational researchers in academia as well as biotech and pharma companies in neuroscience. Read More

#News

#Alzheimer's #Drug discovery #Genetics #Life sciences #Neuroscience #Therapeutics

Is new thinking the key to unlocking Alzheimer’s treatment?

Professor Paul Whiting, Chief Scientific Officer of The Alzheimer’s Research UK UCL Drug Discovery Institute (ARUK UCL DDI), and Stephane Martinez, product manager and neuroscience expert in PerkinElmer’s Life Sciences segment, share expert insights on Alzheimer’s Disease research today and where discovery and therapeutic approaches might be headed next. Read More

#Editor's Choice #News #Opinion

#Drug development #Drug discovery #Funding #Therapeutics

Researchers awarded $12 million for personalised asthma therapies

A group of researchers led by Indiana University School of Medicine’s Benjamin Gaston has been awarded a research programme project grant from the National Heart, Lung and Blood Institute. The award amounts to just over $12 million over the next five years and will fund the development of personalised… Read More

#News

#AI #Drug development #Drug discovery #Machine learning #Therapeutics

Why we are on the cusp of a golden age of medicine 

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find out why he… Read More

#Cancer Research #Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Computer modelling #Data #Drug targets #Novel therapeutics #Therapeutics

New computer modelling could boost drug discovery 

Scientists from Queen’s University Belfast have developed a computer-aided data tool that will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects. The data tool or protocol will uncover a novel class of… Read More

#News

#AI / data analytics / healthtech / informatics #Biosciences #Drug development #Therapeutics

Analytical challenges when characterising complex molecules

Michael-John O’Connor, Director of Biochemical Services at BioPharmaSpec, discusses analysing biosimilars, glycosylated mAbs and PEGylated proteins with Lu Rahman.  LR: Outline the importance of bio-molecules in drug discovery. What is their potential within therapeutic development?    MJOC: The FDA’s recent approval of Biocon’s Semglee (long acting Insulin glargine) is the first example of an interchangeable biosimilar that can be substituted… Read More

#Exclusive Content #News

#Antibodies #Biotherapeutics #Therapeutics

New platform could improve potency and efficacy of therapeutic antibodies 

PerkinElmer is expanding its Horizon Discovery CHOSOURCE platform to include a new expression cell line, CHO-K1 ADCC+, which may improve potency and efficacy of therapeutic antibodies and fusion protein biotherapeutics, as well as reduce dosage requirements and side effects for patients.   This new expression host was built… Read More

#News